- Home
- NUVB vs APLT Comparison
NUVB vs APLT Comparison
Compare NUVB & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVB
- APLT
- Stock Information
- Founded
- NUVB 2018
- APLT 2016
- Country
- NUVB United States
- APLT United States
- Employees
- NUVB N/A
- APLT N/A
- Industry
- NUVB Biotechnology: Pharmaceutical Preparations
- APLT Biotechnology: Pharmaceutical Preparations
- Sector
- NUVB Health Care
- APLT Health Care
- Exchange
- NUVB Nasdaq
- APLT Nasdaq
- Market Cap
- NUVB 850.3M
- APLT 971.6M
- IPO Year
- NUVB N/A
- APLT 2019
- Fundamental
- Price
- NUVB $2.62
- APLT $9.38
- Analyst Decision
- NUVB Strong Buy
- APLT Strong Buy
- Analyst Count
- NUVB 6
- APLT 5
- Target Price
- NUVB $6.17
- APLT $12.50
- AVG Volume (30 Days)
- NUVB 2.1M
- APLT 1.8M
- Earning Date
- NUVB 11-06-2024
- APLT 11-07-2024
- Dividend Yield
- NUVB N/A
- APLT N/A
- EPS Growth
- NUVB N/A
- APLT N/A
- EPS
- NUVB N/A
- APLT N/A
- Revenue
- NUVB $2,162,000.00
- APLT N/A
- Revenue This Year
- NUVB N/A
- APLT N/A
- Revenue Next Year
- NUVB N/A
- APLT $3,169.03
- P/E Ratio
- NUVB N/A
- APLT N/A
- Revenue Growth
- NUVB N/A
- APLT N/A
- 52 Week Low
- NUVB $1.22
- APLT $1.79
- 52 Week High
- NUVB $4.16
- APLT $10.62
- Technical
- Relative Strength Index (RSI)
- NUVB 49.69
- APLT 55.03
- Support Level
- NUVB $2.44
- APLT $8.51
- Resistance Level
- NUVB $3.07
- APLT $9.86
- Average True Range (ATR)
- NUVB 0.17
- APLT 0.61
- MACD
- NUVB -0.01
- APLT -0.09
- Stochastic Oscillator
- NUVB 43.26
- APLT 39.03
About NUVB Nuvation Bio Inc.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes, AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.